300 related articles for article (PubMed ID: 34863080)
81. Isoalantolactone inhibits pancreatic cancer proliferation by regulation of PI3K and Wnt signal pathway.
Zhang C; Huang L; Xiong J; Xie L; Ying S; Jia Y; Yao Y; Song X; Zeng Z; Yuan J
PLoS One; 2021; 16(3):e0247752. PubMed ID: 33661942
[TBL] [Abstract][Full Text] [Related]
82. [Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing Gastric Cancer Through Mammalian Target of Rapamycin].
Rao H; Cheng W; Yu J; An X; Deng H; Zhang Z; Wu F; Ji F; Li S
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Nov; 54(6):1146-1153. PubMed ID: 38162062
[TBL] [Abstract][Full Text] [Related]
83. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance.
Chen H; Zhu X; Sun R; Ma P; Zhang E; Wang Z; Fan Y; Zhou G; Mao R
Invest New Drugs; 2020 Dec; 38(6):1707-1716. PubMed ID: 32468271
[TBL] [Abstract][Full Text] [Related]
84. Three-dimensional environment sensitizes pancreatic cancer cells to the anti-proliferative effect of budesonide by reprogramming energy metabolism.
Ibello E; Saracino F; Delle Cave D; Buonaiuto S; Amoroso F; Andolfi G; Corona M; Guardiola O; Colonna V; Sainz B; Altucci L; De Cesare D; Cobellis G; Lonardo E; Patriarca EJ; D'Aniello C; Minchiotti G
J Exp Clin Cancer Res; 2024 Jun; 43(1):165. PubMed ID: 38877560
[TBL] [Abstract][Full Text] [Related]
85. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.
Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC
Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701
[TBL] [Abstract][Full Text] [Related]
86. Chemopreventive effect of Betulinic acid via mTOR -Caspases/Bcl2/Bax apoptotic signaling in pancreatic cancer.
Guo Y; Zhu H; Weng M; Wang C; Sun L
BMC Complement Med Ther; 2020 Jun; 20(1):178. PubMed ID: 32513155
[TBL] [Abstract][Full Text] [Related]
87. Saikosaponin d modulates the polarization of tumor-associated macrophages by deactivating the PI3K/AKT/mTOR pathway in murine models of pancreatic cancer.
Xu X; Cui L; Zhang L; Yang L; Zhuo Y; Li C
Int Immunopharmacol; 2023 Sep; 122():110579. PubMed ID: 37433245
[TBL] [Abstract][Full Text] [Related]
88. MTOR inhibitor-based combination therapies for pancreatic cancer.
Hassan Z; Schneeweis C; Wirth M; Veltkamp C; Dantes Z; Feuerecker B; Ceyhan GO; Knauer SK; Weichert W; Schmid RM; Stauber R; Arlt A; Krämer OH; Rad R; Reichert M; Saur D; Schneider G
Br J Cancer; 2018 Feb; 118(3):366-377. PubMed ID: 29384525
[TBL] [Abstract][Full Text] [Related]
89. HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B.
Malvi P; Chava S; Cai G; Hu K; Zhu LJ; Edwards YJK; Green MR; Gupta R; Wajapeyee N
Cell Rep Med; 2023 Nov; 4(11):101285. PubMed ID: 37951219
[TBL] [Abstract][Full Text] [Related]
90. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAMTOR2-mediated mTOR activation.
Xu J; Quan G; Huang W; Jiang J
Cell Commun Signal; 2023 Aug; 21(1):223. PubMed ID: 37626304
[TBL] [Abstract][Full Text] [Related]
91. ARHGAP25 Inhibits Pancreatic Adenocarcinoma Growth by Suppressing Glycolysis via AKT/mTOR Pathway.
Huang WK; Chen Y; Su H; Chen TY; Gao J; Liu Y; Yeh CN; Li S
Int J Biol Sci; 2021; 17(7):1808-1820. PubMed ID: 33994864
[TBL] [Abstract][Full Text] [Related]
92. MK8722, an AMPK activator, inhibiting carcinoma proliferation, invasion and migration in human pancreatic cancer cells.
Wang C; Huang B; Sun L; Wang X; Zhou B; Tang H; Geng W
Biomed Pharmacother; 2021 Dec; 144():112325. PubMed ID: 34656065
[TBL] [Abstract][Full Text] [Related]
93. The antitumor effect of the novel agent MCL/ACT001 in pancreatic ductal adenocarcinoma.
Yang J; Li Y; Han X; Pei X; Lin Z; Li C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5717-5728. PubMed ID: 36547690
[TBL] [Abstract][Full Text] [Related]
94. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract][Full Text] [Related]
95. PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers.
Zhong Z; Sepramaniam S; Chew XH; Wood K; Lee MA; Madan B; Virshup DM
Oncogene; 2019 Oct; 38(40):6662-6677. PubMed ID: 31391551
[TBL] [Abstract][Full Text] [Related]
96. GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma.
Sun X; Chu H; Lei K; Ci Y; Lu H; Wang J; Zhou M; Ren H; Zheng T
Pancreatology; 2022 Sep; 22(6):749-759. PubMed ID: 35717305
[TBL] [Abstract][Full Text] [Related]
97. Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer.
De Santis MC; Gozzelino L; Margaria JP; Costamagna A; Ratto E; Gulluni F; Di Gregorio E; Mina E; Lorito N; Bacci M; Lattanzio R; Sala G; Cappello P; Novelli F; Giovannetti E; Vicentini C; Andreani S; Delfino P; Corbo V; Scarpa A; Porporato PE; Morandi A; Hirsch E; Martini M
Gut; 2023 Feb; 72(2):360-371. PubMed ID: 35623884
[TBL] [Abstract][Full Text] [Related]
98. Discovery of GOT1 Inhibitors from a Marine-Derived
Yan S; Qi C; Song W; Xu Q; Gu L; Sun W; Zhang Y
Mar Drugs; 2021 Oct; 19(11):. PubMed ID: 34822459
[TBL] [Abstract][Full Text] [Related]
99. PYGL-mediated glucose metabolism reprogramming promotes EMT phenotype and metastasis of pancreatic cancer.
Ji Q; Li H; Cai Z; Yuan X; Pu X; Huang Y; Fu S; Chu L; Jiang C; Xue J; Zhang X; Li R
Int J Biol Sci; 2023; 19(6):1894-1909. PubMed ID: 37063425
[TBL] [Abstract][Full Text] [Related]
100. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression.
Cheng CS; Tan HY; Wang N; Chen L; Meng Z; Chen Z; Feng Y
Clin Transl Med; 2021 Jun; 11(6):e467. PubMed ID: 34185423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
